SCHEMBL21569716

SCHEMBL21569716

Cc1ccccc1CCNS(=O)(=O)c1c(O)cc(Cl)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
CPB1 P15086 1/20 0.42
ACLY P53396 1/20 0.41
AKR1B1 P15121 1/20 0.38
LMNA P02545 2/20 0.38
KDM4E B2RXH2 2/20 0.38
PKM P14618 2/20 0.38
HPGD P15428 2/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPC1 O15118 1/20 0.37
NR3C1 P04150 1/20 0.37
PGR P06401 1/20 0.37
NR3C2 P08235 1/20 0.37
ALOX15 P16050 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MGAM O43451 1/20 0.36
DAO P14920 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31277514 1.00 L3MBTL1 (0.43) L3MBTL1CPB1ACLYAKR1B1LMNA
SCHEMBL31277145 0.89 MPO (0.41) L3MBTL1ACLYNR3C1PGRNR3C2
SCHEMBL21569715 0.89 MPO (0.41) L3MBTL1ACLYNR3C1PGRNR3C2
SCHEMBL21550407 0.85 L3MBTL1 (0.43) L3MBTL1CPB1ACLYAKR1B1LMNA
SCHEMBL31277291 0.85 L3MBTL1 (0.43) L3MBTL1CPB1ACLYAKR1B1LMNA
SCHEMBL21569704 0.81 L3MBTL1 (0.46) L3MBTL1CPB1AKR1B1LMNAKDM4E
SCHEMBL31500481 0.80 L3MBTL1 (0.51) L3MBTL1CPB1LMNAKDM4EPKM
SCHEMBL21569864 0.79 L3MBTL1 (0.47) L3MBTL1CPB1LMNAKDM4EPKM
SCHEMBL21569707 0.79 TRPV4 (0.49) L3MBTL1CPB1LMNAKDM4EPKM
SCHEMBL9215811 0.78 NR3C1 (0.44) L3MBTL1CPB1KDM4EALDH1A1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US claimed
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity GLUCOX BIOTECH AB (SE) 2025-01-21 US claimed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US claimed
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US disclosed
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity GLUCOX BIOTECH AB (SE) 2025-01-21 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
WO-2019215291-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity NOX4, NOX1, NOX5 L3MBTL1 4858/4885CPB1 3954/4885ACLY 2328/4885
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 L3MBTL1 4838/4885CPB1 4005/4885ACLY 2249/4885
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 L3MBTL1 4838/4885CPB1 4005/4885ACLY 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.